Accéder au contenu
Merck

Dexmedetomidine sedation with and without midazolam for third molar surgery.

Anesthesia progress (2014-04-05)
Megann K Smiley, Simon R Prior
RÉSUMÉ

Twenty-four patients were randomly divided into 2 groups. Intraoperatively, one group received a continuous intravenous infusion of dexmedetomidine alone, whereas the other received a continuous dexmedetomidine infusion plus a small dose of midazolam. Early measurements of patient anxiety and psychomotor performance were lower in patients who had received midazolam. This difference was not seen later in the appointment. An amnesic effect was observed in those patients who received midazolam. This effect, however, did not translate into increased patient satisfaction in the group receiving midazolam. Our findings suggest a prolonged discharge time for patients who had been given midazolam that may be clinically significant. Overall, dexmedetomidine showed an unpredictable sedative response and may be less practical than more common alternatives for oral surgery procedures.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Midazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Midazolam, European Pharmacopoeia (EP) Reference Standard